INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says

INmune Bio (NASDAQ:INMB) had its price target raised by equities researchers at Scotiabank from $22.00 to $23.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the stock. Scotiabank’s price objective indicates a potential upside of 151.92% from the company’s current price.

Several other research firms also recently weighed in on INMB. RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective on the stock. Finally, Alliance Global Partners started coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.00.

INmune Bio Stock Up 10.7 %

INMB opened at $9.13 on Tuesday. The stock’s fifty day moving average is $6.44 and its two-hundred day moving average is $6.11. The company has a market capitalization of $202.41 million, a P/E ratio of -4.19 and a beta of 1.87. INmune Bio has a 52 week low of $4.32 and a 52 week high of $14.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in INmune Bio by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock worth $1,698,000 after purchasing an additional 19,136 shares during the period. Diametric Capital LP grew its holdings in INmune Bio by 24.6% during the fourth quarter. Diametric Capital LP now owns 36,699 shares of the company’s stock worth $171,000 after acquiring an additional 7,244 shares during the period. JPMorgan Chase & Co. raised its position in INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. LPL Financial LLC lifted its holdings in INmune Bio by 33.0% in the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company’s stock valued at $89,000 after acquiring an additional 4,730 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in INmune Bio in the 4th quarter worth approximately $2,221,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.